Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414

Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for

Clinigen Launches Malaysia Office to Strengthen Presence in Southeast Asia
Clinigen Launches Malaysia Office to Strengthen Presence in Southeast Asia


Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s

Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation
Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation


Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in

Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality


Regulatory News:



Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron

Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference


Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3rd Annual Evercore ISI 2020 Virtual

Genus plc Provides Update on Fiscal 2021 Financial Performance
Genus plc Provides Update on Fiscal 2021 Financial Performance


Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the period from July 1, 2020 through November 24, 2020

Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that pursuant to the terms of that previously announced Exchange and Purchase Agreement, dated as of November 4, 2020, by and between Clovis

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences:

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve

Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors
Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors


Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the

Clinigen Expands Partnership With Accord Healthcare in Clinical Services Into France
Clinigen Expands Partnership With Accord Healthcare in Clinical Services Into France


Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service

The Boston Globe Names Deciphera a Top Place to Work for 2020
The Boston Globe Names Deciphera a Top Place to Work for 2020


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitorshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors


Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being

Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted

NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer

Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference : https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA

Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020
Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting


Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting on November 19 through November 21

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine


Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with

Lysogene Reports its Cash Position as of 30 September 2020
Lysogene Reports its Cash Position as of 30 September 2020


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position as of 30

 
THERANEXUS : THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLINICAL DEVELOPMENT PLAN SUBMITTED BY THERANEXUS AND BBDF
THERANEXUS : THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLINICAL DEVELOPMENT PLAN SUBMITTED BY THERANEXUS AND BBDF

Lyon, 19 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) announced securement of the